Journal article
E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation
Abstract
The mammalian target of rapamycin (mTOR) pathway is frequently deregulated and has critical roles in cancer progression. mTOR inhibitor has been widely used in several kinds of cancers and is strongly recommended in patients with hepatocellular carcinoma (HCC) after liver transplantation (LT). However, the poor response to mTOR inhibitors due to resistance remains a challenge. Hypoxia-associated resistance limits the therapeutic efficacy of …
Authors
Ling S; Zhan Q; Jiang G; Shan Q; Yin L; Wang R; Que Q; Wei X; Xu S; Yu J
Journal
American Journal of Transplantation, Vol. 22, No. 10, pp. 2323–2336
Publisher
Elsevier
Publication Date
October 2022
DOI
10.1111/ajt.17124
ISSN
1600-6135